Bruker Fluorescence Microscopy’s Post

🧠 𝗨𝗻𝗰𝗼𝘃𝗲𝗿 𝗻𝗼𝘃𝗲𝗹 𝘁𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀 𝗳𝗼𝗿 𝗱𝗲𝗽𝗿𝗲𝘀𝘀𝗶𝗼𝗻 ▶️ https://lnkd.in/dCmKUnyG In this exciting Inscopix, Inc. webinar, a special guest will unveil the newest findings from a project conducted through the Inscopix Discovery Lab, providing a real-world example of the application of Inscopix miniscope technology to further drug development. In addition, hear more from Dr. Jonathan Nassi on the cutting-edge in vivo imaging assay from the Inscopix Discovery Lab. This innovative approach incorporates miniscope imaging with active behavior to facilitate preclinical pharma studies assessing novel compounds. #depression #neuroscience #Therapeutics #miniscope

Very excited about this collaboration with the PSPP! At Goldenrod Therapeutics, we are developing next-generation, small molecule, oral PDE4B inhibitors for the treatment of severely debilitating diseases that affect the central nervous system and for which current treatments are either inadequate or non-existent. Globally, about 1 in 5 people suffer from chronic pain, an extremely complex and debilitating condition which varies significantly between individuals. Unfortunately, highly addictive opioids are still the most commonly prescribed medications for chronic pain and, despite decades of effort, there are still no exceptional alternatives on the market. Goldenrod's non-opioid small molecule drugs have the potential to change this! Importantly, this partnership marks our second collaboration with an NIH Institutional Program - the first being our acceptance into NIDA's Addiction Treatment Discovery Program (ATDP) in 2022. We are thrilled to work with these key partners, among others, to advance Goldenrod's promising new treatments forward and to address the unmet needs of patients worldwide. #chronicpain #painresearch #paintherapeutics

We are excited to announce that one of our Fannin-founded companies, Goldenrod Therapeutics, has been accepted into the National Institute of Neurological Disorders and Stroke (NINDS) Preclinical Screening Platform for Pain (PSPP). In alignment with the NIH HEAL Initiative, the PSPP is an efficient, rigorous, one-stop screening resource to accelerate discovery of effective, non-addictive, non-opioid pain therapies. The program can assess in vitro and pharmacokinetic profiles, side effect profiles, abuse liability, and efficacy in models relevant to human pain conditions.     Support from the PSPP Program will help accelerate the development of Goldenrod’s small molecule therapeutics towards treating chronic pain, which affects more than 51 million people in the United States alone. We look forward to this partnership and its potential for advancing these promising therapeutics towards the clinic. #Biotech #Neuroscience #Therapeutics #Innovation #Fannin

2D neurotox studies in a fully human co-culture system (IPS-derived sensory neurons and primary Schwann cells) are a fast and reliable way to acquire more human-relevant data for developing therapeutics with off-target neurotoxic concerns. Our platform includes the use of the Yokogawa Cell Voyager CQ1 for imaging and cell analysis. Want to see more? Check out our poster from this year's SOT conference: https://buff.ly/4acHGM1 #microscopymonday #yokogawa #neuroimaging #neurotox #SOTTOX #SOT

🚨𝐁𝐑𝐄𝐀𝐊𝐈𝐍𝐆: 𝐀𝐛𝐛𝐕𝐢𝐞 𝐀𝐜𝐪𝐮𝐢𝐫𝐞𝐬 𝐀𝐥𝐢𝐚𝐝𝐚 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬 𝐢𝐧 $𝟏.𝟒 𝐁𝐢𝐥𝐥𝐢𝐨𝐧 𝐃𝐞𝐚𝐥 𝐭𝐨 𝐀𝐝𝐯𝐚𝐧𝐜𝐞 𝐀𝐥𝐳𝐡𝐞𝐢𝐦𝐞𝐫’𝐬 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭𝐬 AbbVie has announced its acquisition of Aliada Therapeutics, a privately held biotech specializing in early-stage drugs for Alzheimer’s disease. This $1.4 billion acquisition highlights AbbVie’s strategic expansion into neuroscience, underscoring the importance of Aliada’s proprietary technology that enhances blood-brain barrier penetration—a critical challenge in neurodegenerative drug development. Aliada’s approach to crossing the blood-brain barrier could be transformative for Alzheimer’s treatments, potentially improving drug delivery directly to the brain. AbbVie’s investment in this innovative technology marks a significant bet on the future of Alzheimer’s therapy, a field with vast unmet needs and considerable commercial potential. This acquisition aligns with a larger trend of major players targeting novel mechanisms in the Alzheimer’s and neuroscience space. As the industry watches AbbVie’s latest move, it reaffirms the company’s commitment to addressing neurodegenerative diseases and advancing therapeutic frontiers. #Biotech #AbbVie #AliadaTherapeutics #Alzheimers #Neuroscience #BloodBrainBarrier #Pharma

Studying drugs' effects on organoids.... We are excited to announce a research collaboration between Axxam, a leader in Screening technologies and High Content Imaging, and Tessara Therapeutics, renowned for their expertise in creating #humanBrainOrganoids. Together, we develop complex cellular models of co-cultured human neurons and glial cells in microplate formats for image-based analysis using High Content Screening microscopy (Opera Phenix by Revvity). Our collaboration exemplifies the power of combining cutting-edge imaging technology with advanced organoid models to push the boundaries of neuroscience research. 🎥 Check out our latest movie, showcasing a 3D reconstruction of a brain organoid in a miniaturized format. The first seconds provide a maximum projection overview, followed by a detailed representation of the volumetric structure of part of the organoid (left) and a magnified region with higher resolution (right). The green color highlights the β-III tubulin staining for neurites, while the red color indicates the signal from glial cells. This cell culture system can be utilized to test the effects of drugs on human neuronal disease models, providing critical insights into neurogenesis and neuroplasticity within a organ-like context. The use of organoid systems will allow to pharmacologically interrogate yet unprecedented biology. Stay tuned for more updates on our research and the future of drug discovery! #Axxam #TessaraTherapeutics #HighContentImaging #BrainOrganoids #Neuroscience #Innovation #DrugDiscovery #RealBrain

The latest advancements driving neuroscience drug discovery research In this webinar, hosted by DDW and sponsored by ApconiX, you will hear from Dr Isaac Klein, Chief Scientific Officer at Dewpoint Therapeutics, Dr Sam Clark, MD PhD, CEO of Terran Biosciences, and Professor Ruth Roberts, Co-founder and Director of Safety Science at ApconiX.   Dr Klein shares how Dewpoint applies insights into the subcellular organisation of biochemical processes into membrane-less compartments to discover novel drug targets and revolutionary drugs for diseases with high unmet need, including amyotrophic lateral sclerosis (ALS) and Rett Syndrome. Dr Clark’s presentation will cover the intersection of medicinal chemistry and drug discovery as well as how this can help address the unmet medical need for new therapeutics in the neuropsych space. Professor Roberts will explore how an integrated in vitro seizure liability assay can benefit drug discovery for companies exploring central nervous system diseases. What you will learn: • Where are the breakthroughs in neuroscience research? • How are advanced technologies proving beneficial to drug discovery and development? • How is the current unmet need within drug discovery and development for central nervous system (CNS) disorders providing opportunity? A Q&A session follows the webinar presentations. Mon, Sep 30, 2024 3:00 PM - 4:00 PM BST Register today! https://lnkd.in/em3QDi5n #Neuroscience #Drugdiscovery #DrugDevelopment

Recent high-profile failures in Amyotrophic Lateral Sclerosis (ALS) drug clinical trials highlight a critical gap in the drug development process: the need for more reliable cell models to better predict clinical outcomes. Would you like to get quick and reliable answers on the efficacy of your drug candidates targeting ALS? Join our upcoming webinar and explore our ready-to-use in vitro assay: 🔶 Amenable for high-throughput formats 🔶 Multiple disease-relevant readouts 🔶 High robustness and reproducibility Leveraging human iPSC technology, our assay gives you the edge in selecting drug candidates with a higher likelihood of late-stage success. Register with the link in the comments ⬇ #neuroscience #drugdiscovery #ALS

Experimental and computational biophysics to identify vasodilator drugs targeted at TRPV2 using agonists based on the probenecid scaffold. Read the article here: https://lnkd.in/gC-j2WMX

🧠 Neuroscience News 🧠 ▪ Brenig Therapeutics - Announced $65m Series A financing to advance leading pre-clinical #ParkinsonsDisease pipeline. Financing was lead by New Enterprise Associates (NEA), with support from existing investors OrbiMed, Torrey Pines Investment LLC, and BGV (BioGeneration Ventures) ▪ Asceneuron SA raises $100m for #Alzheimer’s drug development. The Series C round was led by Novo Holdings, support by additional investors EQT Group, OrbiMed, SR One Capital Management, Sofinnova Partners as well as GSK Equity Investments and the venture arms of Johnson & Johnson and Merck KGaA. ▪ Reunion Neuroscience - announced that the first patient has been dosed in the RECONNECT Phase 2 clinical trial of RE104 for the treatment of postpartum depression (PPD) ▪ Immunic Therapeutics appoint Jason Tardio as Chief Operating Officer and President to lead internal efforts to prepare for the potential launch of vidofludimus calcium (IMU-838), the company's orally available nuclear receptor related 1 (Nurr1) activator for #MultipleSclerosis ▪ Sage Therapeutics and Biogen halt clinical development of SAGE-324 for essential tremor #Neuroscience and #Psychiatry is a focus area of mine where I've had the pleasure of partnering with some amazing companies. If you're looking for new opportunities in the space, looking to grow your team or to talk about market trends, drop me an email - alex.coppen@apsida.com